A targeted genetic screening panel to identify biallelic variants in TEX44 and CPT1B, and potentially other axonemal genes, in men with unexplained asthenozoospermia. The test aims to differentiate between mitochondrial sheath defects and broader ciliary dyskinesia.
The SWOT analysis reveals a high-precision diagnostic tool with strong biological grounding, but one that faces a critical risk of narrow scope. While it solves a specific molecular gap in mitochondrial sheath diagnosis, its viability depends on expanding the panel to include axonemal genes like LRRC6 to avoid misdiagnosis.
Strengths3
Weaknesses3
Opportunities3
Threats3
A SWOT analysis is essential to weigh the technical strength of the targeted panel against the weakness of potential false negatives from overlapping genetic defects. · Generated 2026-08-05 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated